ABSTRACT
Introduction Attention-deficit/hyperactivity disorder (ADHD) is one of the most common neurodevelopmental disorders of childhood. Up to 50% of children with ADHD may also experience symptoms of emotional dysregulation, such as anger, irritability, and aggression. Emotional dysregulation contributes to adverse health outcomes such as depression and peer problems, yet it is poorly understood, and effective treatment options are lacking. Emerging evidence suggests that sensory processing may play a role in emotional dysregulation. Forty to 50% of children with ADHD may also experience sensory modulation dysfunction, or SMD. SMD is characterized by hypo- or hyperreactivity to pain and sensation. Only one study investigated the relationship of SMD and emotional dysregulation in ADHD; they found a correlation of r=0.45. If SMD drives emotional dysregulation in ADHD, treating SMD has the potential to improve emotional regulation. Further evaluating the relationship between SMD and emotional dysregulation in ADHD is the crucial first step in developing effective treatment options.
Methods Data for this analysis are derived from the baseline assessment of a multi-site, randomized, controlled trial: The Micronutrients for ADHD in Youth (MADDY) Study. The study enrolled children aged 6-12 with a diagnosis of ADHD and symptoms of emotional dysregulation. Using a cross-sectional study design, we will measure the association between emotional dysregulation and SMD at baseline. Emotional dysregulation was measured using the Strengths and Difficulties Questionnaire (SDQ) and a composite score from the Child and Adolescent Symptom Inventory, Version-5 (CASI-5). SMD will be assessed using two subscales from the Temperament in Middle Childhood Questionnaire (TMCQ). To test our hypothesis, we will use simple linear regression. Models will be adjusted for potential confounding variables.
Conclusion Our results will serve to better characterize the relationship between SMD and emotional dysregulation in children with ADHD, which may inform treatment options and diminish adverse health outcomes.
Competing Interest Statement
Dr. Arnold has received research funding from Curemark, Forest, Lilly, Neuropharm, Novartis, Noven, Otsuka, Roche/Genentech, Shire, Supernus, and YoungLiving (as well as NIH and Autism Speaks), has consulted with CHADD, Neuropharm, Organon, Pfizer, Sigma Tau, Shire, Tris Pharma, and Waypoint, and been on advisory boards for Arbor, Ironshore, Novartis, Noven, Otsuka, Pfizer, Roche, Seaside Therapeutics, Sigma Tau, Shire. The other authors have no conflicts of interest to disclose.
Clinical Trial
The protocol for the MADDY study was published on ClinicalTrials.gov (NCT #03252522). This project is a secondary data analysis and does not have a separate ClinicalTrials.gov identifier.
Clinical Protocols
Funding Statement
Dr. Bruton received support from Oregon Health & Science University and by grants from NIH (NIH-NCCIH T32 #AT002688). Funding for the MADDY study has come through private donations to the Nutrition and Mental Health Research Fund, managed by the Foundation for Excellence in Mental Health Care (FEMHC), as well as from a direct grant from FEMHC and funding from the Gratis Foundation. Dr. Johnstone received support from NIH-NCCIH 5R90AT00892403 through the National University for Natural Medicine. Dr. Johnstone's work on study inception and design was funded by NIH-NCCIH T32 AT002688, as well as through support from the Department of Child and Adolescent Psychiatry, Oregon Health & Science University and Oregon Clinical & Translational Research, through the National Center for Advancing Translational Sciences of the National Institutes of Health under award number UL1TR000128. Dr. Leung's position is supported by the Emmy Droog (endowed) chair in Complementary and Alternative Healthcare. The study at the Canadian site is funded by the Nutrition and Mental Health Research Fund, administered by the Calgary Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This project is a secondary data analysis. No clinical research was conducted as part of this project. Only deidentified data was used as part of this project, therefore, IRB oversight was not required. The main study from which these data were obtained, the MADDY study, was approved by the United States Food and Drug Administration (IND #127832), Health Canada (Control #207742), Institutional Review Boards at OHSU IRB #16870, OSU IRB #2017H0188, and by the University of Calgary Conjoint Health Research Ethics Board (CHREB) REB# 170325. The protocol for the MADDY study was published on ClinicalTrials.gov (NCT #03252522).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
This is an update to an earlier analysis plan indexed on MedRxiv. Our original plan was based on a factor analysis of the TMCQ which was in progress and has since been completed. The final factor structure does not include one of our proposed independent variables, sensation seeking, thus this has been dropped. Following a discussion among the coauthors we have also added a sensitivity analysis to the plan. We have also stated that the STROBE guidelines will be used to guide reporting.
Data Availability
Data and code for this project will be made available on GitHub after the project is completed.
